HK1231459A1 - 類胡蘿蔔素衍生物、其藥學上可接受的鹽或者其藥學上可接受的酯類或酰胺類 - Google Patents

類胡蘿蔔素衍生物、其藥學上可接受的鹽或者其藥學上可接受的酯類或酰胺類

Info

Publication number
HK1231459A1
HK1231459A1 HK17105022.2A HK17105022A HK1231459A1 HK 1231459 A1 HK1231459 A1 HK 1231459A1 HK 17105022 A HK17105022 A HK 17105022A HK 1231459 A1 HK1231459 A1 HK 1231459A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutically acceptable
amide
carotenoid derivative
acceptable salt
ester
Prior art date
Application number
HK17105022.2A
Other languages
English (en)
Inventor
藤田岳
小林學史
篠原龍馬
西田康弘
高橋二郎
Original Assignee
Fuji Chem Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuji Chem Ind Co Ltd filed Critical Fuji Chem Ind Co Ltd
Publication of HK1231459A1 publication Critical patent/HK1231459A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/24—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK17105022.2A 2014-05-20 2017-05-18 類胡蘿蔔素衍生物、其藥學上可接受的鹽或者其藥學上可接受的酯類或酰胺類 HK1231459A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014104480 2014-05-20
JP2014247549 2014-12-08
PCT/JP2015/064408 WO2015178404A1 (ja) 2014-05-20 2015-05-20 カロテノイド誘導体、その薬学上許容される塩又はその薬学上許容されるエステル類若しくはアミド類

Publications (1)

Publication Number Publication Date
HK1231459A1 true HK1231459A1 (zh) 2017-12-22

Family

ID=54554071

Family Applications (1)

Application Number Title Priority Date Filing Date
HK17105022.2A HK1231459A1 (zh) 2014-05-20 2017-05-18 類胡蘿蔔素衍生物、其藥學上可接受的鹽或者其藥學上可接受的酯類或酰胺類

Country Status (18)

Country Link
US (1) US10125104B2 (zh)
EP (1) EP3147279A4 (zh)
JP (1) JP6393754B2 (zh)
KR (1) KR101963946B1 (zh)
CN (1) CN106458881B (zh)
AU (1) AU2015262405B2 (zh)
CA (1) CA2948605C (zh)
CL (1) CL2016002940A1 (zh)
HK (1) HK1231459A1 (zh)
IL (1) IL248700B (zh)
MX (1) MX363918B (zh)
NZ (1) NZ726535A (zh)
PH (1) PH12016502303A1 (zh)
RU (1) RU2693455C2 (zh)
SG (1) SG11201609405VA (zh)
TW (1) TWI654171B (zh)
WO (1) WO2015178404A1 (zh)
ZA (1) ZA201607968B (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105461696B (zh) * 2015-12-08 2017-11-24 李秋菊 一种用于脑梗塞康复的药物组合物
JP2021008404A (ja) * 2017-09-27 2021-01-28 アスタファーマシューティカルズ株式会社 変形性関節症改善剤
JP2021028295A (ja) * 2017-11-27 2021-02-25 アスタファーマシューティカルズ株式会社 光学活性のトランス−アスタキサンチン誘導体又はその塩、及びそれらの化合物を含有する組成物
JP2021028301A (ja) * 2017-12-04 2021-02-25 アスタファーマシューティカルズ株式会社 皮膚炎治療剤
JP2021028300A (ja) * 2017-12-04 2021-02-25 アスタファーマシューティカルズ株式会社 掻痒抑制剤
JP2021054718A (ja) * 2018-01-09 2021-04-08 アスタファーマシューティカルズ株式会社 ドライアイ改善剤
CN111727039A (zh) * 2018-02-13 2020-09-29 阿斯塔制药有限公司 大肠炎改善剂
CN112367987A (zh) * 2018-06-05 2021-02-12 旗舰创业创新五公司 活性剂和其用于治疗代谢障碍和非酒精性脂肪性肝病的方法
JP2021176821A (ja) * 2018-08-01 2021-11-11 アスタファーマシューティカルズ株式会社 新規カロテノイド関連誘導体、その塩又はエステル類若しくはアミド類
US20220380306A1 (en) * 2019-09-27 2022-12-01 Cardax,Inc. Astaxanthin esters and methods of use thereof
CN118084755A (zh) * 2024-04-22 2024-05-28 潍坊富邦药业有限公司 一种高水溶性虾青素衍生物及制备方法
CN118063368A (zh) * 2024-04-22 2024-05-24 潍坊富邦药业有限公司 一种水溶性虾青素衍生物及其合成方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100375740C (zh) 2002-02-06 2008-03-19 Dsmip资产公司 虾青素酯
US20080008798A1 (en) 2002-02-06 2008-01-10 Arnold Gloor Salts of astaxathin esters
EP1500645B1 (en) 2002-04-30 2009-07-15 Suntory Holdings Limited Astaxanthin medium-chain fatty acid ester, process for producing the same and composition containing the ester
US7763649B2 (en) 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US20050004235A1 (en) 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US7723327B2 (en) 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US20050059635A1 (en) 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US20050143475A1 (en) 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US20050148517A1 (en) 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
CN1708480B (zh) 2002-07-29 2010-12-15 卡达克斯药物公司 用于抑制和改善疾病的类胡萝卜素结构类似物
US7345091B2 (en) 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050026874A1 (en) 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US20050009788A1 (en) 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling connexin 43 expression
US7375133B2 (en) 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050049248A1 (en) 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US7521584B2 (en) 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US7320997B2 (en) 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US20050059659A1 (en) 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
JP2006515516A (ja) * 2003-01-09 2006-06-01 ビーエーエスエフ　アクチェンゲゼルシャフト 遺伝子改変されたＢｌａｋｅｓｌｅａ属の生物を使用する、カロチノイドまたはそれらの前駆体を製造するための方法、上記方法によって製造されたカロチノイドまたはそれらの前駆体、ならびにそれらの使用
EP1750723A1 (en) * 2004-04-14 2007-02-14 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
CA2606329A1 (en) * 2005-03-09 2006-09-21 Cardax Pharmaceuticals, Inc. Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders
US20060270590A1 (en) * 2005-03-29 2006-11-30 Lockwood Samuel F Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
CA2613169A1 (en) * 2005-05-02 2006-11-09 Cardax Pharmaceuticals, Inc. Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of cox inhibitors
JP2007176814A (ja) * 2005-12-27 2007-07-12 Yoshihiro Futamura 炎症性サイトカイン産生抑制作用を有するゼアキサンチン誘導体、それからなる食品製剤、化粧品、抗炎症剤
US20090099061A1 (en) 2006-01-27 2009-04-16 Foss Bente J Synthesis of carotenoid analogs or derivatives with improved antioxidant characteristics
JP2007238564A (ja) 2006-03-10 2007-09-20 Fujifilm Corp カロチノイド−コラーゲンペプチド縮合体
WO2008023283A2 (en) 2006-08-25 2008-02-28 Omnica Gmbh Stabilized esters of lutein
EP1952845A1 (en) * 2007-01-26 2008-08-06 DSMIP Assets B.V. Use of an astaxathin derivative for cosmetic purposes
WO2008106606A2 (en) * 2007-02-28 2008-09-04 Cardax Pharmaceuticals, Inc. Carotenoid analogs and derivatives in the treatment of prostate cancer
US8063101B2 (en) * 2007-03-23 2011-11-22 Cardax Pharmaceuticals, Inc. Carotenoid analogs and derivatives for the prevention of platelet aggregation
CL2008002577A1 (es) 2007-08-31 2009-10-23 Basf Se Procedimiento para preparar una solucion de un derivado de astaxantina en un aceite comestible que comprende suspender el derivado de astaxantina en aceite comestible cuyo diametro de particulas es de 0,5-50 um, donde el derivado de astaxantina comprende al menos un 70% en peso de al menos un compuesto de la formula (i).
DK2403363T3 (da) 2009-03-05 2013-03-18 Basf Se Formulering af Astaxanthin-derivater og anvendelse heraf II
CN102340998B (zh) 2009-03-05 2014-03-26 巴斯夫欧洲公司 虾青素衍生物的配制剂及其应用i
CN102341006A (zh) 2009-03-05 2012-02-01 巴斯夫欧洲公司 虾青素衍生物的粉状组合物ii
EP2403360B1 (de) 2009-03-05 2016-08-10 Basf Se Formulierung von astaxanthin-derivaten und deren verwendung iii
CN102341007A (zh) 2009-03-05 2012-02-01 巴斯夫欧洲公司 生产虾青素衍生物的溶液的方法
DK2403359T3 (da) 2009-03-05 2013-04-22 Basf Se Pulverformet sammensætning af astaxanthin-derivater I
TWI501946B (zh) * 2010-02-08 2015-10-01 Basf Se 蝦紅素二琥珀酸二甲酯之製造方法
MX2017003237A (es) 2014-09-11 2017-06-29 Basf Se Metodo para producir esteres de astaxantina.

Also Published As

Publication number Publication date
CA2948605C (en) 2019-12-24
US20170081289A1 (en) 2017-03-23
RU2693455C2 (ru) 2019-07-03
NZ726535A (en) 2019-02-22
MX2016015236A (es) 2017-02-23
IL248700B (en) 2019-06-30
IL248700A0 (en) 2017-01-31
ZA201607968B (en) 2018-05-30
RU2016149777A (ru) 2018-06-21
WO2015178404A1 (ja) 2015-11-26
MX363918B (es) 2019-04-05
RU2016149777A3 (zh) 2018-12-28
KR101963946B1 (ko) 2019-03-29
JP6393754B2 (ja) 2018-09-19
EP3147279A1 (en) 2017-03-29
PH12016502303B1 (en) 2017-02-13
TWI654171B (zh) 2019-03-21
EP3147279A4 (en) 2018-01-10
JPWO2015178404A1 (ja) 2017-04-20
TW201625521A (zh) 2016-07-16
AU2015262405B2 (en) 2019-01-03
KR20170007304A (ko) 2017-01-18
CL2016002940A1 (es) 2017-09-01
CA2948605A1 (en) 2015-11-26
SG11201609405VA (en) 2016-12-29
PH12016502303A1 (en) 2017-02-13
US10125104B2 (en) 2018-11-13
CN106458881A (zh) 2017-02-22
AU2015262405A1 (en) 2016-12-08
CN106458881B (zh) 2019-07-30

Similar Documents

Publication Publication Date Title
HK1231459A1 (zh) 類胡蘿蔔素衍生物、其藥學上可接受的鹽或者其藥學上可接受的酯類或酰胺類
EP3099171A4 (en) Dihydropteridinone derivatives and uses thereof
EP3154972A4 (en) Azamophinan derivatives and use thereof
EP3195805A4 (en) Stethoscope head and stethoscope comprising same
SG11201607045SA (en) Pyrazole amide derivative
EP3177147A4 (en) Dihydropteridinone derivatives and uses thereof
ZA201607658B (en) Carboxamide derivatives
EP3118211A4 (en) Amide compounds and methods for the production and use thereof
IL256339A (en) Result of pyrazole or its pharmacy salt
SG11201609311RA (en) Carboxamide derivatives
IL249356A0 (en) A derivative of 2-acylaminothiazole or a salt thereof
EP3130340A4 (en) Isoacteoside derivative and preparation method and use thereof
ZA201607919B (en) Dipicolylamine derivatives and their pharmaceutical uses
EP3112343A4 (en) Amide derivatives
EP3176150A4 (en) Medium-chain acyl basic amino acid derivative
EP3187488A4 (en) Novel amino-phenyl-sulfonyl-acetate derivative and use thereof
IL272366A (en) Adamantylmethylamine derivatives and their uses as a pharmaceutical preparation
EP3244887A4 (en) 5-methoxytryptophan and its derivatives and uses thereof
IL248801A0 (en) Carboxamide history
EP3368509A4 (en) FLUORINATED AMIDE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS
EP3252038A4 (en) N-benzoate group substituted benzopyrroline-2-one derivative and use thereof